Themis Bioscience GmbH clinical trials
Acquired by Merck & Co., Inc, Jun 2020 · source ↗
The registry lists 8 studies whose lead sponsor is Themis Bioscience GmbH. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 11, 2025.
Before and after it joined Merck & Co., Inc
- First submitted before Themis Bioscience GmbH became part of Merck & Co., Inc
- 8
- First submitted after Themis Bioscience GmbH became part of Merck & Co., Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Status
- Completed
- 7
- Withdrawn
- 1
Registry sponsor names on this page
- Themis Bioscience GmbH8 studies
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 8 of 8. All Merck & Co., Inc studies →
- A Trial to Evaluate the Optimal Dose of MV-LASV (V182-001)CompletedNCT04055454Phase 1
Sponsor listed in the registry: Themis Bioscience GmbH · First submitted before Themis Bioscience GmbH became part of Merck & Co., Inc
- Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)CompletedNCT03807843Phase 2
Sponsor listed in the registry: Themis Bioscience GmbH · First submitted before Themis Bioscience GmbH became part of Merck & Co., Inc
- Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001)CompletedNCT02996890Phase 1
Sponsor listed in the registry: Themis Bioscience GmbH · First submitted before Themis Bioscience GmbH became part of Merck & Co., Inc
- Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP (V187-001)CompletedNCT04033068Phase 1
Sponsor listed in the registry: Themis Bioscience GmbH · First submitted before Themis Bioscience GmbH became part of Merck & Co., Inc
- Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya VaccineCompletedNCT02861586Phase 2
Sponsor listed in the registry: Themis Bioscience GmbH · First submitted before Themis Bioscience GmbH became part of Merck & Co., Inc
- Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)CompletedNCT03635086Phase 2
Sponsor listed in the registry: Themis Bioscience GmbH · First submitted before Themis Bioscience GmbH became part of Merck & Co., Inc
- Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic AreaCompletedNCT03101111Phase 2
Sponsor listed in the registry: Themis Bioscience GmbH · First submitted before Themis Bioscience GmbH became part of Merck & Co., Inc
- A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal TractWithdrawnNCT04195373Phase 1
Sponsor listed in the registry: Themis Bioscience GmbH · First submitted before Themis Bioscience GmbH became part of Merck & Co., Inc